top of page
Search

What is AHCC? Exploring Its Immune and Clinical Effects

In recent years, the search for natural supplements that can robustly support the immune system has gained significant momentum. Among the myriad of options available, Active Hexose Correlated Compound (AHCC) stands out as one of the most extensively researched functional foods. Derived from the mycelia of the shiitake mushroom (Lentinula edodes), this standardized extract is primarily marketed as an immune-support supplement. Its applications have been studied across various cell and animal models, as well as in a modest number of human trials, predominantly serving as an adjunct therapy in infection and cancer settings.

This comprehensive guide delves into the mechanisms, clinical uses, and safety profile of AHCC, providing a scientifically grounded overview of its potential benefits.

AHCC Immune Effects and Mechansim

AHCC Mechanisms and Immune Effects

The core composition of AHCC is what makes it biologically active and effective. It consists mainly of low-molecular-weight α-glucan oligosaccharides, enriched with essential amino acids and minerals . This unique structure allows for efficient absorption and rapid interaction with the body's immune pathways.

Scientific investigations have elucidated that AHCC activates intestinal epithelial cells and monocytes. It achieves this by engaging the TLR2/TLR4–MyD88–NF-κB/MAPK signaling pathways .


The activation of these pathways induces the production of critical cytokines, including IL-6, IL-8, MCP-1, and TNF-α. Furthermore, studies conducted on mice have demonstrated that AHCC increases the levels of secretory IgA and regulatory/Th1 cytokines, such as IL-10 and IFN-γ, within the gut fluid .


A substantial body of reviews and human data highlights AHCC's ability to modulate Natural Killer (NK) cells and T cells (CD4+, CD8+). This modulation often manifests as an increase in their absolute numbers or an enhancement of their functional cytokine production capabilities .


Clinical and Preclinical Uses

The therapeutic potential of AHCC has been explored across a variety of medical conditions. The following table summarizes the main findings from key clinical and preclinical studies regarding its application in different indications.


Benefits, Safety, and Uncertainties

The current landscape of human data suggests that AHCC may offer possible benefits primarily as an adjunct therapy, rather than a stand-alone cure. Its utility is most notable in managing infections—including HPV—and certain cancers, functioning largely through immune modulation .

Regarding safety, the short-term use of AHCC appears to be generally well tolerated by most individuals. However, some reported side effects include itching, gastrointestinal (GI) upset, headache, fatigue, and cramps . There is also a theoretical risk that its immune-stimulating properties could exacerbate autoimmune diseases.

It is crucial to acknowledge the limitations of the current evidence base. Many of the existing studies are characterized by small sample sizes, open-label designs, or are restricted to animal models. Consequently, robust, large-scale randomized controlled trials are still limited, leaving some uncertainties regarding its definitive clinical efficacy.


Summary

In conclusion, AHCC is an immune-active mushroom mycelia extract that significantly influences both gut and systemic immunity, with a particular emphasis on enhancing the function of NK and T cells. Preclinical data and early human studies point toward its potential adjunctive roles in combating infections, supporting cancer therapy, and managing inflammatory conditions. Furthermore, it boasts a generally favorable short-term safety profile.

However, the evidence remains preliminary. Critical aspects such as optimal dosing, long-term safety, and the true extent of clinical benefit necessitate larger, well-controlled human trials before AHCC can be unequivocally considered an established medical treatment.


References

  • Madolangan, J., Yusuf, I., Wahyudin, E., & Djaharuddin, I. (2025). Effects of Active Hexose Correlated Compound (AHCC®) on Clinical and Laboratory Response of Pulmonary Tuberculosis Patients. Jurnal Respirologi Indonesia. https://doi.org/10.36497/jri.v45i4.820

  • Ritz, B. (2011). Active Hexose Correlated Compound (AHCC) and Immune Outcomes in Humans: A Review. .

  • Mallet, J., Graham, É., Ritz, B., Homma, K., & Matar, C. (2016). Active Hexose Correlated Compound (AHCC) promotes an intestinal immune response in BALB/c mice and in primary intestinal epithelial cell culture involving toll-like receptors TLR-2 and TLR-4. European Journal of Nutrition, 55, 139-146. https://doi.org/10.1007/s00394-015-0832-2

  • Gao, Y., Zhang, D., Sun, B., Fujii, H., Kosuna, K., & Yin, Z. (2006). Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunology, Immunotherapy, 55, 1258-1266. https://doi.org/10.1007/s00262-005-0111-9

  • Daddaoua, A., Martínez-Plata, E., Ortega-González, M., Ocón, B., Aranda, C., Zarzuelo, A., Suárez, M., De Medina, F., & Martínez Augustín, O. (2013). The nutritional supplement Active Hexose Correlated Compound (AHCC) has direct immunomodulatory actions on intestinal epithelial cells and macrophages involving TLR/MyD88 and NF κ B/MAPK activation.. Food chemistry, 136 3-4, 1288 95. https://doi.org/10.1016/j.foodchem.2012.09.039 2 / 3

  • Kamiyama, T., Orimo, T., Wakayama, K., Kakisaka, T., Shimada, S., Nagatsu, A., Asahi, Y., Aiyama, T., Kamachi, H., & Taketomi, A. (2022). Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia. Integrative Cancer Therapies, 21. https://doi.org/10.1177/15347354211073066 Ritz, B. (2008).

  • Supplementation with active hexose correlated compound increases survival following infectious challenge in mice.. Nutrition reviews, 66 9, 526-31. https://doi.org/10.1111/j.1753-4887.2008.00085.x

  • Miura, T., & Kulkarni, A. (2017). AHCC Nutritional Supplement and the Immune Response. , 427-434. https://doi.org/10.1201/9781315118901-25

  • Corradetti, B., Vaiasicca, S., Mantovani, M., Virgili, E., Bonucci, M., & Ferri, I. (2019). Bioactive Immunomodulatory Compounds: A Novel Combinatorial Strategy for Integrated Medicine in Oncology? BAIC Exposure in Cancer Cells. Integrative Cancer Therapies, 18. https://doi.org/10.1177/1534735419866908

  • Farasatinasab, M., & Nassiri, S. (2022). Could Active Hexose Correlated Compound (AHCC) Currently Be an Appropriate Choice to Clear Human Papillomavirus Infection?. The Journal of Clinical Pharmacology, 62. https://doi.org/10.1002/jcph.2118

  • Cao, Z., Chen, X., Lan, L., Zhang, Z., Du, J., & Liao, L. (2014). Active hexose correlated compound potentiates the antitumor effects of low-dose 5-fluorouracil through modulation of immune function in hepatoma 22 tumor-bearing mice. Nutrition Research and Practice, 9, 129 - 136. https://doi.org/10.4162/nrp.2015.9.2.129

  • Fatehchand, K., Santhanam, R., Shen, B., Erickson, E., Gautam, S., Elavazhagan, S., Mo, X., Belay, T., Tridandapani, S., & Butchar, J. (2017). Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells. PLoS ONE, 12. https://doi.org/10.1371/journal.pone.0181729

  • Suknikhom, W., Lertkhachonsuk, R., & Manchana, T. (2017). The Effects of Active Hexose Correlated Compound (AHCC) on Levels of CD4+ and CD8+ in Patients with Epithelial Ovarian Cancer or Peritoneal Cancer Receiving Platinum Based Chemotherapy. Asian Pacific Journal of Cancer Prevention : APJCP, 18, 633 - 638. https://doi.org/10.22034/apjcp.2017.18.3.633

  • Mascaraque, C., Suárez, M., Zarzuelo, A., De Medina, S., & Martínez-Augustín, O. (2014). Active hexose correlated compound exerts therapeutic effects in lymphocyte driven colitis.. Molecular nutrition & food research, 58 12, 2379-82. https://doi.org/10.1002/mnfr.201400364

  • Smith, J., Mathew, L., Gaikwad, A., Rech, B., Burney, M., Faro, J., Lucci, J., Bai, Y., Olsen, R., & Byrd, T. (2019). From Bench to Bedside: Evaluation of AHCC Supplementation to Modulate the Host Immunity to Clear High-Risk Human Papillomavirus Infections. Frontiers in Oncology, 9. https://doi.org/10.3389/fonc.2019.00173

  • Shin, M., Park, H., Maeda, T., Nishioka, H., Fujii, H., & Kang, I. (2019). The Effects of AHCC®, a Standardized Extract of Cultured Lentinura edodes Mycelia, on Natural Killer and T Cells in Health and Disease: Reviews on Human and Animal Studies. Journal of Immunology Research, 2019. https://doi.org/10.1155/2019/3758576

  • Ghoneum, M., Wimbley, M., Salem, F., Mcklain, A., Attallah, N., & Gill, G. (1995). Immunomodulatory and anticancer effects of active hemicellulose compound (AHCC). International Journal of Immunotherapy, 11, 23-28. (2021). O10 1: Community led tuberculosis and COVID 19 risk communication in the Vietnamese migrant population in Japan. Respirology. https://doi.org/10.1111/resp.14149_56

  • Park, H., Boo, S., Park, I., Shin, M., Takahashi, T., Takanari, J., Homma, K., & Kang, I. (2022). AHCC®, a Standardized Extract of Cultured Lentinula Edodes Mycelia, Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.87587

 
 
bottom of page